GPR18
ENSG00000125245
Target class
GPCR
Chromosome
13
- Chemical probe available
- No
- Other names
- DRV2
- Target name
- GPR18
- Gene name
- G protein-coupled receptor 18
- Gene symbol
- GPR18
- Protein name
- N-arachidonyl glycine receptor (NAGly receptor) (G-protein coupled receptor 18)
- Gene biotype
- Protein coding
- Gene family
- G protein-coupled receptors, Class A orphans
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 5
- Highest tissue expression
- 22.53
- Tissue specificity (Gini)
- 0.806
- Tissue specificity (tau)
- 0.975
- KEGG gene identifiers
- hsa:2841
- Protein interaction confidence
- 0.778125
- Protein interaction partners
- 8
- R-HSA-373076
- R-HSA-418594
- End position
- 99261744
- Start position
- 99254732
- Chromosome
- 13
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Cytoplasmic vesicle membrane .
- PubMed 24762058
- PubMed 27018161
- Tissue specificity (tau)
- 0.974525
- Expression inequality (Gini)
- 0.806425
Expression in transcripts per million
- Testis
- 22.53
- Spleen
- 10.89
- Whole Blood
- 3.14
- Cells - EBV-transformed lymphocytes
- 2.95
- Small Intestine - Terminal Ileum
- 1.9
Expression in transcripts per million
- Testis22.53
- Spleen10.89
- Whole Blood3.14
- Cells - EBV-transformed lymphocytes2.95
- Small Intestine - Terminal Ileum1.9
- Lung0.78
- Cervix - Ectocervix0.62
- Prostate0.62
- Vagina0.6
- Esophagus - Mucosa0.52
- Colon - Transverse0.48
- Cervix - Endocervix0.44
- Adipose - Visceral (Omentum)0.41
- Thyroid0.41
- Minor Salivary Gland0.39
- Skin - Not Sun Exposed (Suprapubic)0.36
- Bladder0.36
- Uterus0.31
- Liver0.3
- Colon - Sigmoid0.3
- Artery - Coronary0.26
- Nerve - Tibial0.26
- Stomach0.25
- Ovary0.25
- Pituitary0.25
And 29 more, listed on the interactive page.
Cellular components
- GO:0005886
- GO:0004930
- GO:0005515
Related records
Trials (473)
- 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers
- A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
- A Clinical Trial on the Antipsychotic Properties of Cannabidiol
- A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy
- A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis
- A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
- A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking
- A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
- A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions
- A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
- A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
- A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
- A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- A Randomized Controlled Trial of Oral CBD for the Treatment of Upper Extremity Musculoskeletal Pain
- A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
- A Study of Cannabidiol in Young Adult Cannabis Users
- A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
- A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
- A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy